Susquehanna Fundamental Investments LLC Purchases New Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Susquehanna Fundamental Investments LLC acquired a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 8,390 shares of the company's stock, valued at approximately $233,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of AKRO. abrdn plc raised its stake in shares of Akero Therapeutics by 118.7% during the 4th quarter. abrdn plc now owns 269,782 shares of the company's stock valued at $7,505,000 after purchasing an additional 146,424 shares during the period. Rock Springs Capital Management LP grew its holdings in Akero Therapeutics by 1.4% during the 4th quarter. Rock Springs Capital Management LP now owns 946,499 shares of the company's stock valued at $26,332,000 after buying an additional 13,100 shares in the last quarter. Sei Investments Co. bought a new stake in shares of Akero Therapeutics during the fourth quarter valued at about $303,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Akero Therapeutics by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 540,692 shares of the company's stock worth $15,042,000 after buying an additional 8,096 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Akero Therapeutics by 14.0% in the fourth quarter. Wells Fargo & Company MN now owns 61,867 shares of the company's stock valued at $1,721,000 after acquiring an additional 7,587 shares during the period.

Insider Buying and Selling at Akero Therapeutics

In related news, COO Jonathan Young sold 607 shares of Akero Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $27,242.16. Following the transaction, the chief operating officer now directly owns 200,540 shares of the company's stock, valued at $9,000,235.20. The trade was a 0.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Andrew Cheng sold 30,000 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $52.73, for a total transaction of $1,581,900.00. Following the sale, the chief executive officer now directly owns 686,062 shares of the company's stock, valued at $36,176,049.26. The trade was a 4.19 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 219,208 shares of company stock worth $9,556,494. 7.94% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

AKRO has been the topic of a number of analyst reports. UBS Group upped their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Canaccord Genuity Group upped their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. Finally, Citigroup upped their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $76.29.

Akero Therapeutics Trading Down 6.0 %

NASDAQ:AKRO traded down $2.54 during trading hours on Friday, reaching $39.85. The company's stock had a trading volume of 1,332,231 shares, compared to its average volume of 891,466. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The firm has a market capitalization of $3.18 billion, a price-to-earnings ratio of -10.63 and a beta of -0.12. The firm has a 50-day simple moving average of $41.21 and a 200-day simple moving average of $37.50. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Research analysts expect that Akero Therapeutics, Inc. will post -3.99 EPS for the current fiscal year.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.